12:30 PM
 | 
May 15, 2018
 |  BC Extra  |  Company News

Gilead boosts foothold in cell therapy with new facilities

The Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) said Tuesday it has leased a new facility in Hoofddorp, the Netherlands to engineer cell therapies, including Yescarta axicabtagene ciloleucel, for patients in Europe. An MAA for Yescarta is under EMA review.

The facility is expected to be fully operational in 2020.

The approvals of CAR T cell therapies Yescarta as well as Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) last year have prompted the field to get serious about industrializing manufacturing of the cells to improve reproducibility and lower costs (see BioCentury Innovations, April 19).

Tuesday's news follows Kite's April purchase of a new building in Santa Monica, Calif. from Astellas Pharma Inc. (Tokyo:4503) for cell therapy research, development and to expand clinical manufacturing capabilities. Kite is also leasing a facility in Gaithersburg, Md. to support a 2016 cooperative research and development agreement (CRADA) with the National Cancer Institute to develop adoptive cell therapies targeting patient-specific tumor neoantigens.

Gilead lost $0.06 to $66.99 on Monday.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD